estrogen receptor positive

estrogen receptor positive

Oncology Breast CA cells with a receptor to which estrogens can attach; this is associated with an improved prognosis as the CA usually responds to antiestrogen therapy that blocks the receptors. See Estrogen receptor.
References in periodicals archive ?
The following five investigators and studies have been awarded grants through the program to date:Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute A Phase Ib/IIa Study of Palbociclib in Combination With Everolimus and Exemestane in Postmenopausal Women With Estrogen Receptor Positive and HER2 Negative Metastatic Breast Cancer,Ewa Mrozek, MD, The Ohio State University Comprehensive Cancer Center - Arthur G.
According to the researchers, young women who are current or recent smokers and had been smoking a pack a day for at least 10 years, had a 60 percent increased risk of estrogen receptor positive breast cancer.
found 60 percent increased risk of developing one of the most common types of breast cancer called estrogen receptor positive, in young women who smoked a pack of cigarettes daily, for more than ten years.
The researchers found that 2 percent of breast cancer patients tested, who were identified as estrogen receptor positive (ER+) and therefore potential candidates to benefit from endocrine therapy, actually had a variant of the estrogen receptor called "delta Exon 7 deletion.
Some women cannot tolerate estrogen deprivation, but for those with estrogen receptor positive breast tumors, anastrazole significantly improves survival.
The Oncotype test is a validated 21-gene quantitative RT-PCR assay that has been developed for use in formalin-fixed paraffin embedded breast cancer samples that are estrogen receptor positive and node negative.
In estrogen receptor positive disease, the late recurrences keep coming; you keep on getting them in years 5-9, 10-14, and 15-plus," he said.
While we do not have a chemoprevention strategy that directly targets the estrogen receptor-negative tumors of importance to high-risk patients, a reduction in estrogen receptor positive tumors still is of value.
Cyclin D1 expression and patient outcome after tamoxifen therapy in estrogen receptor positive metastatic breast cancer.
Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer.
Sgroi, director of breast pathology at Massachusetts General Hospital, the majority of breast cancer patients are estrogen receptor positive, and the risk of late distant recurrence remains a substantial concern.

Full browser ?